Filing Flows › Harmony Biosciences Holdings (HRMY) › Q3 2026
Harmony Biosciences Holdings (HRMY) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Harmony Biosciences Holdings (HRMY) reported revenue of $269M for the third quarter 2026 (Q3 2026), +12% from a year earlier and +3% from the quarter before. Operating margin was 20.2%, net earnings $48.2M (17.9% of revenue).
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%, net earnings $48.2M, operating cash flow $76.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $269M | +3% | +12% |
| Gross profit | $188M | -5% | +5% |
| Operating profit | $54.2M | -39% | -17% |
| Net earnings | $48.2M | -36% | -5% |
| Operating cash flow | $76.7M | -17% | -29% |
What changed
Revenue was $268.9M in Q3 2026, up 12% year over year and up 3% from the previous quarter.
Gross margin was 70.0%, down 5.1 points from Q3 2025. Operating profit was $54.2M, a 20.2% margin (down 7.2 points year over year). Operating profit fell $11.3M even though revenue rose $29.5M versus Q3 2025, so costs grew faster than sales. Operating expenses grew 17% against revenue growth of 12%. The fastest-growing cost line was Research & development (+30%). Net earnings were $48.2M, down 5% year over year. The effective tax rate was 18.7%.
Operating cash flow was $76.7M (down 29% year over year), 159% of net earnings. Non-cash charges added back $6.0M of depreciation and amortization and $8.0M of share-based compensation. Working capital and other items added $14.5M.
Questions
What was Harmony Biosciences Holdings' revenue in the third quarter 2026?
Harmony Biosciences Holdings (HRMY) reported revenue of $269M for the third quarter 2026 (Q3 2026), +12% from a year earlier and +3% from the quarter before.
Was Harmony Biosciences Holdings profitable in the third quarter 2026?
Operating profit was $54.2M (20.2% of revenue) and net earnings $48.2M.